The Procurement Lens.
Category intelligence · R&D · Contract manufacturing (CDMO)

Contract manufacturing (CDMO)

Outsourced development and manufacturing of drug substance and drug product: biologics, small molecules, peptides, ADCs, fill-finish.

Strategic · high switching cost, long qualification, few qualified sites

At a glance

CDMO growth, 2026

Lonza 2026 guide
+11-12%
CER; margin 33-34%
OfficialManufacturing Chemist · 14 Oct 2026
Samsung Biologics revenue
+18.5%
Q3; 2026 guide raised to 20%
OfficialKorea Times · 21 Oct 2026
WuXi AppTec 9M revenue
+39%
Backlog RMB 76.7bn
OfficialFierce Pharma · Oct 2026
Divi's revenue
+35.4%
Q2 FY27; custom synthesis-led
CDMO capacity is tightening. Lonza, Samsung Biologics, Divi's and Piramal are all growing double digits, while US tariffs and BIOSECURE push buyers away from China. Secure capacity and tech-transfer terms early, and add a second qualified site for critical products.

Exhibit 1CDMO growth, latest quarter

Revenue growth year on year

WuXi AppTec (9M)+39%Piramal CDMO+36%Divi's (total revenue)+35.4%Samsung Biologics+18.5%Lonza (2026 guide)+11.5%Syngene-9%
OfficialCompany results, Q3 2026 / Q2 FY27 · Oct-Nov 2026
Showing: Global

The category on a page

What it isOutsourced process development and commercial manufacturing of drug substance and product.
How bigLonza H1 2026 sales CHF 3.4bn; WuXi AppTec 2026 guide about $9.1-9.3bn.
Market structureGlobal leaders (Lonza, Samsung Biologics, WuXi, Thermo Fisher), Indian players (Divi's, Piramal, Syngene), niche specialists.
PositioningStrategic: switching takes 18-36 months of tech transfer and regulatory filing.
Key riskCapacity, quality failures, geopolitical restrictions on China.
Primary leverLong-term capacity agreements, dual sourcing, tech-transfer and price-review terms.

Exhibit 2Where contract manufacturing sits

Profit impact against supply risk, R&D subcategories

ROUTINELEVERAGEBOTTLENECKSTRATEGICContract manufacturingClinical researchAPIsLab suppliesProfit impact →Supply risk →
JudgementThe Procurement Lens assessment

Exhibit 3Margins at leading CDMOs

Latest reported

Samsung Biologics (operating)42.9%Divi's (EBITDA)42.6%Lonza (CORE EBITDA guide)33.5%Syngene (EBITDA)18%
OfficialCompany results · Oct-Nov 2026

Exhibit 4Samsung Biologics quarterly revenue

KRW trillion

Q3 20251.26Q2 20261.32Q3 20261.49

Typical savings vs single-source renewal

Price, minimum volumes and batch failure terms

3%8%
0%7.5%15%
JudgementThe Procurement Lens judgement for a tight market

Value levers

In order of value.

01Secure capacity with flexible commitments

Reserve slots with take-or-pay bands, not fixed volumes.

Samsung Biologics running Plants 1-4 at full capacity
OfficialHerald Corp
02Qualify a second site

Dual source critical products, ideally in a different country.

BIOSECURE and tariffs raise single-site risk
03Tariff and duty terms

Agree who pays Section 232 duty and when prices reset.

Sartorius paid EUR 28m tariff compensation
OfficialSartorius
04Batch failure and right-first-time terms

Supplier bears cost of failed batches it causes.

Samsung strike disrupted batches
OfficialDaily Pharm
05Index raw materials, fix conversion

Pass through only indexed inputs; fix conversion costs.

Stops margin creep
JudgementThe Procurement Lens
06Tech-transfer and exit rights

Own process data; agree transfer support and cost.

Switching takes 18-36 months
JudgementThe Procurement Lens

How to buy it

Sourcing routeStrategic CDMO plus qualified second site; development work by mini-bid.
Pricing modelPrice per batch or kg with indexed raw materials; capacity reservation fee credited against orders.
Contract termsCapacity bands, batch failure liability, quality agreement, tariff clause, tech transfer and exit.

KPIs to track

For the monthly review

On-time in-full batchesRight-first-time rateDeviations and CAPAsCost per batch vs indexCapacity reserved vs used

Where most buyers are, and what good looks like

Most buyers todayBest practice
SourcingSingle site→Dual qualified sites
CapacityOrder when needed→Rolling 3-year reservations
PricingFixed price list→Indexed inputs, fixed conversion
RiskAnnual audit→Geopolitical and tariff mapping
ExitNot planned→Tech-transfer package agreed

What AI changes

More in the AI disruption tab.

AI process modelling shortens development.
Digital twins raise yields.
AI quality review speeds batch release.

Full written analysis

Written live for Contract manufacturing (CDMO) and your region, grounded on the figures above. Public data only.

Written live for this category and region when the page opens in a browser.

Sources

Figures checked 16 Nov 2026. Tags: Official = published by the source; Derived = calculated from published figures; Judgement = The Procurement Lens view.